Table 3.

Predictors of cancer-specific mortality, locoregional failure, distant failure (all univariate analyses).

Variable	CSM			LRF			DF
	HR	95%CI	p	HR	95%CI	p	HR	95%CI	p
Age at diagnosis
continuous	1.02	0.98–1.06	0.32	1.00	0.97–1.04	0.82	1.00	0.96–1.04	0.95
Gender (v male)
female	0.77	0.23–2.53	0.66	0.93	0.32–2.70	0.89	0.31	0.04–2.30	0.25
Race (v white)
on-whiten	1.83	0.70–4.81	0.22	1.67	0.64–4.37	0.30	1.50	0.44–5.14	0.52
KPS (v ≥90)
<90	2.83	1.26–6.35	0.01	1.52	0.69–3.35	0.30	1.01	0.36–2.85	0.99
T-classification (v T1–T2)
T3–T4	3.41	1.58–7.37	<0.01	2.94	1.40–6.18	<0.01	3.87	1.53–9.78	<0.01
N-classification (v N0–1)
N2–N3	1.85	0.75–4.54	0.18	1.32	0.59–2.98	0.50	4.79	1.11–20.7	0.04
Tobacco Use (v ≤10 pack-years)
>10 pack-years	2.26	0.96–5.30	0.06	2.80	1.14–6.91	0.03	1.62	0.62–4.23	0.32
HPV status (v negative)
positive	0.42	0.17–1.03	0.06	0.52	0.22–1.21	0.13	0.45	0.15–1.35	0.16
unknown	0.57	0.22–1.48	0.25	0.63	0.24–1.67	0.35	0.90	0.30–2.68	0.85
Site (v oropharynx)
larynx	0.96	0.41–2.26	0.92	1.40	0.65–3.01	0.39	0.63	0.21–1.89	0.41
Chemotherapy (v CRT)
BRT	3.33	1.42–7.78	<0.01	0.99	0.37–2.61	0.98	2.01	0.78–5.37	0.14

Abbreviations: CSM, cancer-spcific mortality; LRF, locoregional failure; DF, distant failure; CRT, chemoradiotherapy; BRT, bioradiotherapy; KPS, Karnofsky performance status; HPV, human papillomavirus; HR, hazard ratio; 95%CI, 95% confidence interval.